Department of Astronautical Science and Mechanics, Harbin Institute of Technology (HIT), P.O. Box 301, No. 92 West Dazhi Street, Harbin 150001, People's Republic of China.
Department of Astronautical Science and Mechanics, Harbin Institute of Technology (HIT), P.O. Box 301, No. 92 West Dazhi Street, Harbin 150001, People's Republic of China.
Acta Biomater. 2021 Jul 1;128:100-119. doi: 10.1016/j.actbio.2021.04.050. Epub 2021 May 5.
Transcatheter closure has been widely accepted as a highly effective way to treat abnormal blood flows and/or embolization of thrombus in the heart. It allows the closure of four types of congenital heart defects (CHDs) and stroke-associated left atrial appendage (LAA). The four types of CHDs include atrial septal defect (ASD), patent foramen ovale (PFO), patent ductus arteriosus (PDA), and ventricular septal defect (VSD). Advancements in the materials and configurations of occlusion devices have spurred the transition from open-heart surgery with high complexity and morbidity, or lifelong medication with a high risk of bleeding, to minimally invasive deployment. A variety of occlusion devices have been developed over the past few decades, particularly novel ones represented by biodegradable and 3D-printed occlusion devices, which are considered as next-generation alternatives to conventional Nitinol-based occlusion devices due to biodegradability, customization, and improved biocompatibility. The aim here is to comprehensively review the next-generation occlusion devices in terms of materials, configurations, manufacturing methods, deployment strategies, and (if available) experimental results or clinical data. The current challenges and the direction of future work are also proposed. STATEMENT OF SIGNIFICANCE: Implantation of occlusion devices has become a widely accepted and highly effective treatment for occluding abnormal blood/thrombus flow within the heart. Due to the serious complications such as erosion and displacement of conventional Nitinol-based occluders, next-generation occluders with reduced risk of complications and improved biocompatibility has emerged. Here, we comprehensively review the next-generation occluders developed for atrial septal defect (ASD), patent foramen ovale (PFO), patent ductus arteriosus (PDA), ventricular septal defect (VSD), and left atrial appendage (LAA), with special emphasis on biodegradable occluders. Besides, intelligent materials (e.g., automatically deployable shape memory polymers) and rapid customized manufacturing methods (3D/4D printing) for the fabrication of occluders are also introduced. Lastly, the directions of future work are highlighted.
经导管封堵术已被广泛接受,成为治疗心脏异常血流和/或血栓栓塞的有效方法。它可以闭合四种先天性心脏病(CHD)和与中风相关的左心耳(LAA)。四种 CHD 包括房间隔缺损(ASD)、卵圆孔未闭(PFO)、动脉导管未闭(PDA)和室间隔缺损(VSD)。封堵装置的材料和结构的进步推动了从高复杂性和高发病率的开胸手术,或高出血风险的终身药物治疗,向微创部署的转变。过去几十年已经开发出了各种封堵装置,特别是具有生物可降解性和 3D 打印封堵装置等新型封堵装置,由于其生物可降解性、定制性和改善的生物相容性,被认为是传统基于 Nitinol 的封堵装置的下一代替代品。这里的目的是全面审查下一代封堵装置的材料、配置、制造方法、部署策略以及(如果有)实验结果或临床数据。还提出了当前的挑战和未来工作的方向。
封堵装置的植入已成为一种广泛接受且非常有效的治疗方法,用于封堵心脏内异常的血液/血栓血流。由于传统基于 Nitinol 的封堵器存在严重的并发症,如侵蚀和移位,因此出现了具有较低并发症风险和改善的生物相容性的下一代封堵器。在这里,我们全面审查了用于房间隔缺损(ASD)、卵圆孔未闭(PFO)、动脉导管未闭(PDA)、室间隔缺损(VSD)和左心耳(LAA)的下一代封堵器,特别强调了可生物降解的封堵器。此外,还介绍了用于制造封堵器的智能材料(例如,自动可展开形状记忆聚合物)和快速定制制造方法(3D/4D 打印)。最后,强调了未来工作的方向。